Fig. 1: Overview of BMS-PRISM platform. | Communications Biology

Fig. 1: Overview of BMS-PRISM platform.

From: Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Fig. 1

Solid tumor cell lines were individually infected with Cas9 and 26-bp barcode and tested for CRISPR editing efficiency before archived into BMS-PRISM library. These engineered cell lines were then subpooled and banked according to cancer indications for convenient handling. A full or focused collection of cell lines can be used for the compound as well as CRISPR/Cas9 knockout screening to evaluate drug response or gene essentiality in a single run. Relative cell line abundance after various treatments can be determined by PCR amplification of barcodes and next-generation sequencing.

Back to article page